Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
75,000
Employees75,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
75,000
Employees75,000

PFE Key Statistics

Market cap
151.20B
Market cap151.20B
Price-Earnings ratio
19.60
Price-Earnings ratio19.60
Dividend yield
6.47%
Dividend yield6.47%
Average volume
40.48M
Average volume40.48M
High today
$27.28
High today$27.28
Low today
$26.58
Low today$26.58
Open price
$27.02
Open price$27.02
Volume
34.27M
Volume34.27M
52 Week high
$27.94
52 Week high$27.94
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

Pfizer(PFE) stock is priced at $26.64, giving the company a market capitalization of 151.2B. It carries a P/E multiple of 19.60 and pays a dividend yield of 6.5%.

As of 2026-03-15, Pfizer(PFE) stock has fluctuated between $26.58 and $27.28. The current price stands at $26.64, placing the stock +0.2% above today's low and -2.4% off the high.

Pfizer(PFE) shares are trading with a volume of 34.27M, against a daily average of 40.48M.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

In the last year, Pfizer(PFE) shares hit a 52-week high of $27.94 and a 52-week low of $20.92.

PFE News

Simply Wall St 16h
China Obesity Approval Puts Pfizer’s GLP 1 Bet In Sharper Focus

China has approved Pfizer's GLP-1 obesity therapy Xianweiying (ecnoglutide), granting the company commercialization rights in mainland China. The therapy was o...

China Obesity Approval Puts Pfizer’s GLP 1 Bet In Sharper Focus
TipRanks 17h
Pfizer Quietly Arms Pipeline for Next Growth Wave

Pfizer ( (PFE) ) has been popular among investors this week. Here is a recap of the key news on this stock. Claim 70% Off TipRanks Premium Unlock hedge fund-lev...

TipRanks 2d
Pfizer Targets Pediatric Ulcerative Colitis With New Etrasimod Trial: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. is launching a Phase 2 trial to test how its drug etrasimod works in children...

Analyst ratings

55%

of 29 ratings
Buy
34.5%
Hold
55.2%
Sell
10.3%

More PFE News

TipRanks 2d
Pfizer’s New Tafamidis Tablet Study Signals Strategic Lifecycle Move for PFE

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) is launching a Phase 1 study called “A PHASE 1, OPEN-LABEL, RANDOMIZED,...

TipRanks 3d
Pfizer Advances Early-Stage Cancer Candidate PF-07994525, Extending Its Oncology Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has launched a new early-stage cancer trial titled “An Open-Label Phase...

Nasdaq 3d
PFE May 1st Options Begin Trading

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the May 1st expiration. At Stock Options Channel , our YieldBoost formula has...

PFE May 1st Options Begin Trading
TipRanks 4d
Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. (PFE) has completed a Phase 2 study called “A Phase 2, Randomized, Partially...

Simply Wall St 4d
Pfizer Tariff Exemptions And US$70b Pledge Reshape Valuation Debate

Pfizer, NYSE:PFE, has secured multi year exemptions from proposed 100% US tariffs on imported patented medicines. In return, the company has agreed to invest $...

Pfizer Tariff Exemptions And US$70b Pledge Reshape Valuation Debate
Investor's Business Daily 5d
Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up

Technology Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up Licensing BridgeBio (BBIO) stock popped Tuesday on a notable shake-up in the pa...

Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer's Patent Shake-Up
Simply Wall St 5d
Pfizer Valuation Check After New Tilrekimig Phase 2 Success And Pipeline Progress

Pfizer (PFE) just reported positive Phase 2 topline data for tilrekimig in adults with moderate to severe atopic dermatitis. The trial met its main efficacy goa...

Pfizer Valuation Check After New Tilrekimig Phase 2 Success And Pipeline Progress

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.